By Paul Ziobro
Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms.
Marvai, a San Diego company, said Tuesday that the acquisition would expand the ability of it and TriLink BioTechnologies to enable customers to develop next-generation mRNA and Crispr nucleic-acid based therapies.
Marvai Chief Executive Trey Martin said that Molecular Assemblies is an original leader in enzymatic oligo synthesis, and its team has made significant advancement in designing and developing an enzymatic DNA synthesis platform with advantages over traditional chemical synthesis.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
January 28, 2025 16:14 ET (21:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。